Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067119 · ClinicalTrials.gov registry record · Phase 3
Aggrenox Prevention of Access Stenosis
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 649
- Enrollment target
NCT00067119 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 649 participants.
The verdict
NCT00067119, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 649 participants
- Enrollment target
Study Summary
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
Interventions
- DRUG Placebo
- DRUG Aggrenox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 649 participants |
| Start Date | 2003-01-01 |
| Est. Completion | 2008-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067119
The ClinicalTrials.gov registry entry for NCT00067119 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 649 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00067119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067119 about?
NCT00067119 is a clinical study titled "Aggrenox Prevention of Access Stenosis". The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
What is the current status of trial NCT00067119?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 649 participants. The study started on 2003-01-01. Estimated completion is 2008-01-31.
What interventions are being tested in trial NCT00067119?
The interventions under investigation include: Placebo (DRUG), Aggrenox (DRUG).
Who is sponsoring clinical trial NCT00067119?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.